Aarti Drugs share price
You have to be logged in to add this to Watchlist.- ₹474.30(-1.49%)May 20, 2025 15:29:57 PM IST
- NSE
- BSE
- Vol : 229.11K (NSE + BSE)Last 20 day avg : 993.83 K
Aarti Drugs is trading -1.49% lower at Rs 474.30 as compared to its last closing price. Aarti Drugs has been trading in the price range of 487.65 & 464.95. Aarti Drugs has given 4.39% in this year & 12.18% in the last 5 days. Aarti Drugs has TTM P/E ratio 18.50 as compared to the sector P/E of 24.50.There are 1 analysts who have initiated coverage on Aarti Drugs. There are 0.00 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 62.85 Crores in its last quarter.Listed peers of Aarti Drugs include Hikal (-0.09%), Sequent Scientific (-4.57%), Aarti Drugs (-1.49%).The Mutual Fund holding in Aarti Drugs was at 8.75% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Aarti Drugs was at 2.25% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 20, 2025, 02:31 PM UTC
- Dividend YieldLower than industry0.21Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.20The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values26.13Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility1.04Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.45The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 9.16% from Rs 676.76 crore to Rs 619.99 crore, year-on-year
- The company has grown its March quarter profit by 32.85% from Rs 47.31 crore to Rs 62.85 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 444.63
- R2
- 540.52
- R3
- 592.03
- S1
- 297.23
- S2
- 245.72
- S3
- 149.83
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Hikal | Bullish | 404.45 | -0.09 | 4,983.05 | 95.49 | 3.8 | 0.31 | 29.28 |
| Sequent Scientific | Moderately Bullish | 169.20 | -4.57 | 4,235.11 | - | 6.91 | - | 26.17 |
| Aarti Drugs | Bullish | 474.30 | -1.49 | 4,328.93 | 24.79 | 3.03 | 0.22 | 20.87 |
| Suven Life Sciences | Bullish | 206.00 | -0.96 | 4,492.32 | - | 37.42 | - | - |
| Orchid Pharma | Bearish | 731.00 | -3.71 | 3,713.19 | 40.20 | 3.33 | - | 10.33 |
- Promoter(s) holds a high stake in the company at 55.48%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.03 percentage points from previous quarter
- Mutual Funds holding has increased by 0.97 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-06 | Audited Results |
| 2025-01-29 | Quarterly Results & Interim Dividend |
| 2024-10-24 | Quarterly Results |
| 2024-08-26 | Buy Back of Shares |
| 2024-07-26 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE767A01016
- BSE Code524348
- NSE CodeAARTIDRUGS
Aarti Drugs is trading at 474.30 as on Tue May 20 2025 09:59:57. This is -1.49% lower as compared to its previous closing price of 481.45.
The market capitalization of Aarti Drugs is 4328.93 Cr as on Tue May 20 2025 09:59:57.
The average broker rating on Aarti Drugs is Hold. The breakup of analyst rating is given below -
- 0.00 analysts have given a strong buy rating
- 0.00 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Aarti Drugs is 634.90 whereas the 52 wk low is 312.50
Aarti Drugs can be analyzed on the following key metrics -
- TTM P/E: 18.50
- Sector P/E: 24.50
- Dividend Yield: 0.21%
- D/E ratio: 0.45
Aarti Drugs reported a net profit of 168.16 Cr in 2025.
The Mutual Fund Shareholding was 8.75% at the end of 31 Mar 2025.